Financial Data and Key Metrics Changes - Total revenue for 2025 was $172.4 million, consisting of $124.8 million in Revuforj net revenue, $42.4 million of Niktimvo collaboration revenue, and $5.1 million in milestones and royalties [35] - Revuforj net revenue increased by 38% in the fourth quarter compared to the third quarter, driven by strong demand [35] - Niktimvo net revenue for 2025 reached $151.6 million, surpassing first-year launch benchmarks set by Rezurock [19][35] Business Line Data and Key Metrics Changes - Revuforj generated $125 million in net revenue in 2025, with a 38% growth in net revenue and a 35% growth in prescriptions quarter-over-quarter in Q4 [6][7] - Niktimvo saw a 22% increase in net revenue quarter-over-quarter in Q4, contributing $42 million in collaboration revenue to Syndax in 2025 [8][19] Market Data and Key Metrics Changes - The KMT2A patient population is approaching 50% penetration within the first year of Revuforj's launch, with approximately 1,050 patients treated commercially [12] - NPM1 patients represented about 30% of new patient starts, with expectations for this number to grow significantly [46][47] Company Strategy and Development Direction - Syndax aims to expand its market share in menin inhibition, targeting a total addressable market opportunity exceeding $10 billion [9] - The company is focused on advancing its pipeline, including pivotal trials for revumenib and axatilimab, to unlock new market opportunities [10][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued success of Revuforj and Niktimvo, supported by strong customer relationships and market access [7][9] - The company is well-funded with $394 million in cash and equivalents, expecting to reach profitability without additional capital [37] Other Important Information - Syndax completed enrollment in the MAXPIRe trial for axatilimab in idiopathic pulmonary fibrosis, with top-line data expected in Q4 2026 [30] - The company is positioned to deliver impactful real-world evidence supporting revumenib's clinical use [29] Q&A Session Summary Question: What factors are driving the increase in KMT2A maintenance therapy post-transplant? - Management noted that the growth in KMT2A maintenance therapy is driven by a significant number of patients returning for maintenance after transplant, with expectations for continued growth [43] Question: What is the expected steady-state percentage of NPM1 patient starts? - Management anticipates that the percentage of NPM1 patient starts will grow meaningfully throughout the year, with current estimates around 30% [46][47] Question: What are the benchmarks for the IPF trial to determine the go-forward decision? - The primary endpoint is the annualized rate of decline in forced vital capacity, with expectations for a statistically significant and clinically meaningful difference compared to historical controls [49][50] Question: What is the fastest path to a pivotal trial for IPF if the data reads out positively? - Management indicated that they would be as expeditious as possible in designing the next trial, with plans for a phase 3 trial following a positive phase 2 outcome [54][55] Question: Are physicians comfortable with the dose of Revuforj in maintenance therapy? - Management confirmed that physicians are becoming increasingly comfortable with the dosing for maintenance therapy, supported by ongoing studies [64] Question: What is the strategy for moving Revuforj into newly diagnosed fit KMT2A patients? - The strategy includes a randomized study planned in collaboration with the NCI, focusing on innovative approaches to reduce morbidity while maintaining efficacy [68][69]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $172.4 million, consisting of $124.8 million in Revuforj net revenue, $42.4 million of Niktimvo collaboration revenue, and $5.1 million in milestones and royalties [34] - Revuforj net revenue increased by 38% in the fourth quarter compared to the third quarter, driven by strong demand [34] - Niktimvo net revenue for 2025 reached $151.6 million, surpassing first-year launch benchmarks set by Rezurock [18] Business Line Data and Key Metrics Changes - Revuforj generated $125 million in net revenue in 2025, with a 38% growth in net revenue and a 35% growth in prescriptions quarter-over-quarter in Q4 [4][5] - Niktimvo saw a 22% increase in net revenue quarter-over-quarter in Q4, contributing $42 million in collaboration revenue to Syndax in 2025 [6][34] Market Data and Key Metrics Changes - The KMT2A business is experiencing growth as the number of patients on therapy post-transplant increases, with approximately one-third of KMT2A patients treated with Revuforj proceeding to stem cell transplant [15] - The NPM1 market opportunity is expanding, with the addressable patient population tripling to 6,500 patients following the label expansion for Revuforj [12] Company Strategy and Development Direction - The company aims to continue investing in strategic priorities to fuel growth, including advancing life cycle and frontline programs to unlock over $10 billion in total addressable market opportunity [8] - Syndax is focused on establishing Revuforj as the menin inhibitor of choice in the relapsed refractory setting and the first menin inhibitor approved in the frontline, targeting a $5 billion-plus market opportunity [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued success of both Revuforj and Niktimvo, supported by multiple growth drivers and a well-funded position to invest in commercial and development priorities [8][34] - The company anticipates that the average treatment duration for Revuforj will extend from 4-6 months in the first year to 6-12 months in the second year as treatment patterns mature [17] Other Important Information - The company completed enrollment in the MAXPIRe trial for axatilimab in idiopathic pulmonary fibrosis, with top-line data expected in Q4 2026 [29] - Syndax is well-funded with $394 million in cash, equivalents, and marketable securities at the end of 2025, expecting to reach profitability without the need for additional capital [37] Q&A Session Summary Question: What factors are driving the increase in KMT2A maintenance therapy post-transplant? - Management noted that the growth in KMT2A has been significant, with a rising number of patients returning for maintenance therapy post-transplant, increasing from 35%-40% to 40%-45% [42][43] Question: What is the expected steady-state percentage for NPM1 patient starts? - Management expects the percentage of NPM1 patient starts to grow significantly, potentially reaching a 50/50 split with KMT2A patients as awareness and access improve [45][48] Question: What are the criteria for determining the go-forward decision on the IPF indication? - The primary endpoint for the IPF study is the annualized rate of decline in forced vital capacity, with management looking for statistically significant and clinically meaningful results compared to historical controls [50][51] Question: What is the strategy for moving Revuforj into newly diagnosed fit KMT2A patients? - Management is pursuing an innovative approach with the RAVEN trial, aiming to combine Revuforj with venetoclax to potentially reduce morbidity while achieving similar outcomes to intensive chemotherapy [64][70]